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Abstract
The synthesis and in vitro evaluation of a new series of salvinorin A analogues substituted at the
C(2) position with natural amino acids is reported. Compound 12, containing Val, displayed high
affinity and full agonist activity at the kappa-opioid receptor. Analogues with bulky and/or
aromatic residues were inactive, showing the importance of size and electronegativity of C(2)-
substituents for binding affinity of salvinorin A derivatives.
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A neoclerodane diterpenoid salvinorin A (SA) (1), the active ingredient of the Mexican plant
Salvia divinorum, is a selective kappa-opioid receptor (KOR) agonist with potent in vivo
activity (Fig. 1).1 Recent reports point out a potential role in the treatment of functional
gastrointestinal (GI) disorders, which is in accord with the traditional use of S. divinorum
extracts. SA potently inhibits smooth muscle contractility and motility in vivo in the upper
and lower GI, as well as influences the epithelial ion transport in a KOR-dependent manner
under both physiological and pathophysiological conditions.2 Pharmacokinetic studies in
animals and in humans indicate that SA is rapidly degraded and that its in vivo effects are
short-lasting, regardless of route of administration.3 Therefore numerous attempts have been
made to synthesize SA derivatives with potent affinity at KOR and prolonged in vivo
actions.2 The structure-activity relationship (SAR) studies of SA have demonstrated that the
size and electronegativity of the substituent at the C(2) position is critical for activity at
opioid receptors. It was shown that SA derivatives with spatially restrained (3-4 carbon
atoms) lipophilic groups at C(2) display highest binding affinity and potency at KOR.4-9
However, incorporation of non-lipophilic substituents, such as amines and amino acids also
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resulted in potent and selective KOR ligands.6;8 Interestingly, bulkier substituents tend to
reduce KOR affinity and in some cases increase mu-opioid receptor (MOR) affinity.2
In an attempt to further investigate the role of C(2) in SA binding at KOR we synthesized a
series of derivatives substituted in this position with natural non-aromatic and aromatic
amino acids and evaluated their in vitro affinities and potencies. Previous studies showed
that the introduction of an aromatic moiety in position 2 increased affinity at MOR.10
Therefore, N-(9-fluorenylmethoxycarbonyl) (Fmoc)-protected derivatives were also
synthesized and their affinities compared with those of respective non-protected analogues.
SA (1) was isolated from the leaves of S. divinorum and purified as previously described.11
Compound 1 was converted to salvinorin B (2), which served as the starting material for the
preparation of the C(2)-modified analogs 3–14 (Table 1). Compounds 3-8 were synthesized
from N-Fmoc-protected amino acids using N-methylmorpholine as a catalyst and TBTU as a
coupling reagent (Scheme 1).12 Analogs 9-14 were obtained from respective N-Fmoc-
protected derivatives by deprotection with piperidine.13;14
Spectral data (1H NMR, 13C NMR, high-resolution mass) consistent with the proposed
structures were obtained for all the compounds prepared in this study.
The KOR radioligand binding assays were conducted according to previously described
procedures and the results are presented in Tables 2 and 3.15
[35S]GTPγS binding assays at MOR, DOR and KOR were performed for analogue 12 and
SA, which was used as a reference compound. The in vitro pharmacological data for SA and
12 are listed in Table 4.
Preliminary in vitro binding data in opioid receptor-expressing cells showed that the
introduction of N-Fmoc-protected amino acids at the C(2) position of SA resulted in loss of
affinity at KOR, depending on the amino acid incorporated and the radiolabelled ligand used
(Table 2). Only in the case of the Val-substituted analogue (12) did the removal of the Fmoc
protecting group significantly increase its ability to displace selective ligands at KOR
binding sites, making it almost equipotent with the parent compound, SA. Interestingly, the
Ala-derivative (10) displayed good affinity at KOR against [3H]U69,593, but did not
displace KOR antagonist binding, as assessed with [3H]diprenorphine. Concentration-
response curves showed that analogue 12 had high affinity and selectivity at KOR (Ki values
of 42.0 ± 2.05 and 0.75 ± 0.62 nM for 12 and SA, respectively; Table 3), while the affinity
of 10 was in a μM range (Table 3). To determine the agonist activity of 12 at KOR,
[35S]GTPγS binding assays were performed. The potency of Val-substituted derivative (12)
was lower than that of the parent compound (see Table 4); however, the novel analogue was
a full agonist at KOR (Table 4).
Amino acid analogues of SA substituted at the C(2) position were reported earlier, but only
N-Boc-Gly-derivative displayed good affinity at KOR (90 ± 10 nM).8 The introduction of
N-Ac-Gly, N,N-diMeGly and N,N-diMeGly gave inactive compounds, while the Gly and
Sar analogues were unstable.6 In our study the modification with Val resulted in a potent
and selective KOR agonist, with affinity in the nM range. These data suggest that the C(2)
position in the structure of SA is important for its interaction with the opioid receptors and
that only small, non-aromatic amino acids fit into the binding pocket of KOR.
This is in good agreement with a recently published paper by McGovern et al. on molecular
modelling of C(2)-analogues of SA.16 A region of bulk tolerance, falling within a receptor
hydrophobic pocket, was observed around the C(2) position, extending approximately three
carbon atoms in length from the carbonyl carbon. It has also been shown that the methyl and
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carbonyl groups, as well as a hydrophobic moiety at a terminal position of the C(2)
substituent are important for optimal ligand affinity. Interestingly, the structure of Val-
derivative, which seems to be well-tolerated by the putative binding pocket, accommodates
all above mentioned criteria.
Unexpectedly, in the study of Beguin et al.6 and in our assays, the Ala-derivative did not
displace [3H]diprenorphine from its binding at KOR. However, here we observed that the
Ala-substituted analogue displayed μM affinity against [3H]U69,593, clearly demonstrating
that the choice of the radiolabeled compound can influence the reported binding affinity
data.
In conclusion, we were able to obtain a series of novel amino acid analogues of SA, of
which the Val-derivative displayed highest affinity at KOR, comparable to that of the parent
compound. Due to relative ease of our approach and the availability of reagents the synthetic
strategy used in this study may result in a vast library of analogues and could become the
method of choice in preparation of novel derivatives based on SA structure.
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Structure of salvinorin A (1), salvinorin B (2) and new amino acid analogues.
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Synthesis of amino acid analogues of salvinorin A. Reagents and conditions: a) salvinorin B
(2), appropriate N-Fmoc-amino acids, TBTU, N-methylmorpholine, CH2Cl2, b)
deprotection with piperidine in CH2Cl2.
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12 Val 213 ± 15.0 828 ± 275 117.74
SA - 0.2 ± 0.1 703 ± 179 100.00
Data are mean ± SEM of four experiments.
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